Effective Date: Monday, January 08, 2018 Test Updates

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, January 08, 2018

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 1 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Test Name Test Method / Specimen Stability Scope Units Reference Discontinue Code Name CPT Code Req. Comments

Bupropion and Metabolite Confirmation 54212B • (DUID/DRE), Blood (Forensic) Bupropion and Metabolite Confirmation, 5466B • Blood Bupropion and Metabolite Confirmation, 52012B • Blood (Forensic) Bupropion and Metabolite Confirmation, 5466SP • Serum/Plasma Bupropion and Metabolite Confirmation, 52012SP • Serum/Plasma (Forensic) 9122B Bupropion and Metabolite Screen, Blood • Bupropion and Metabolite Screen, 9122SP • Serum/Plasma 0803B Bupropion and Metabolite, Blood • Bupropion and Metabolite, 0803SP • Serum/Plasma Carbamazepine and Metabolite 54215B Confirmation (DUID/DRE), Blood • (Forensic) Carbamazepine and Metabolite 54215U Confirmation (Qualitative) (DUID/DRE), • Urine (Forensic) Carbamazepine and Metabolite 52015B • Confirmation, Blood (Forensic) Carbamazepine and Metabolite 52015SP • Confirmation, Serum/Plasma (Forensic) Carbamazepine and Metabolite 52015U • Confirmation, Urine (Forensic) 0970B Carbamazepine and Metabolite, Blood • Carbamazepine and Metabolite, 0970SP • Serum/Plasma Carbamazepine-10,11-Epoxide, 0975SP • Serum/Plasma 0975U Carbamazepine-10,11-Epoxide, Urine • 2915U Dextro / Levo Methorphan - Total, Urine • Dextro / Levo Methorphan Confirmation - 54452U Total (Qualitative) (DUID/DRE), Urine • (Forensic) Dextro / Levo Methorphan Confirmation - 52481U • Total, Urine (Forensic) Dextro / Levo Methorphan Screen - Total, 9205U • Urine Dextro/Levo Methorphan Confirmation - 5495U • Total, Urine Dextro/Levo Methorphan Confirmation, 5495SP • Serum/Plasma Dextro/Levo Methorphan Confirmation, 52451SP • Serum/Plasma (Forensic)

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 2 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Test Name Test Method / Specimen Stability Scope Units Reference Discontinue Code Name CPT Code Req. Comments

Dextro/Levo Methorphan Screen, 9205SP • Serum/Plasma 2915SP Dextro/Levo Methorphan, Serum/Plasma • Dextromethorphan and Metabolite Ratio - 2917U • Total, Urine Dextrorphan / Levorphanol - Total, Urine 10153U • (CSA) Dextrorphan / Levorphanol Confirmation - 54349U Total (Qualitative) (DUID/DRE), Urine • (Forensic) Dextrorphan / Levorphanol Confirmation - 5497U • Total, Urine Dextrorphan / Levorphanol Confirmation - 52061U • Total, Urine (Forensic) Dextrorphan / Levorphanol Confirmation, 5117SP • Serum/Plasma Dextrorphan / Levorphanol Confirmation, 52061SP • Serum/Plasma (Forensic) Dextrorphan / Levorphanol Screen - 9206U • Total, Urine Dextrorphan / Levorphanol Screen, 2506SP • Serum/Plasma Guaifenesin Confirmation (Qualitative) 54252U • (DUID/DRE), Urine (Forensic) Guaifenesin Confirmation, Blood 52052B • (Forensic) Guaifenesin Confirmation, Serum/Plasma 52052SP • (Forensic) Guaifenesin Confirmation, Urine 52052U • (Forensic) 2185B Guaifenesin, Blood • 2185SP Guaifenesin, Serum/Plasma • 2185U Guaifenesin, Urine • Lamotrigine Confirmation (DUID/DRE), 54259B • Blood (Forensic) Lamotrigine Confirmation (Qualitative) 54259U • (DUID/DRE), Urine (Forensic) Lamotrigine Confirmation, Blood 52059B • (Forensic) Lamotrigine Confirmation, Serum/Plasma 52059SP • (Forensic) Lamotrigine Confirmation, Urine 52059U • (Forensic) 2484B Lamotrigine, Blood • 2484SP Lamotrigine, Serum/Plasma • 2484U Lamotrigine, Urine •

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 3 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Test Name Test Method / Specimen Stability Scope Units Reference Discontinue Code Name CPT Code Req. Comments

Methadone Confirmation (Drug Impaired 55060U Driving/DRE Toxicology), Urine • (Forensic) (CSA) IN/LA Methadone and Metabolite (DUID/DRE), 10038SP • Serum/Plasma (Forensic) (CSA) Methadone and Metabolite (Qualitative) 10038U • (DUID/DRE), Urine (Forensic) (CSA) Methadone and Metabolite Confirmation 55047U (Drug Impaired Driving/DRE Toxicology), • Urine (Forensic) (CSA) IN/LA Methadone and Metabolite Confirmation 54005U (Qualitative) (DUID/DRE), Urine • (Forensic) Methadone and Metabolite Confirmation, 5682SP • Serum/Plasma Methadone and Metabolite Confirmation, 50015SP • Serum/Plasma (Forensic) Methadone and Metabolite Confirmation, 5682U • Urine Methadone and Metabolite Confirmation, 50015U • Urine (Forensic) Methadone and Metabolite, 8722SP • Serum/Plasma 8722U Methadone and Metabolite, Urine • 3225SP Nuedexta®, Serum/Plasma • Oxcarbazepine/Eslicarbazepine Acetate 54293B as Metabolite Confirmation (DUID/DRE), • Blood (Forensic) Oxcarbazepine/Eslicarbazepine Acetate 52093B as Metabolite Confirmation, Blood • (Forensic) Oxcarbazepine/Eslicarbazepine Acetate 52093SP as Metabolite Confirmation, • Serum/Plasma (Forensic) Oxcarbazepine/Eslicarbazepine Acetate 52093U as Metabolite Confirmation, Urine • (Forensic) Oxcarbazepine/Eslicarbazepine Acetate 3265B • as Metabolite, Blood Oxcarbazepine/Eslicarbazepine Acetate 3265SP • as Metabolite, Serum/Plasma Phencyclidine (DUID/DRE), 10044SP • Serum/Plasma (Forensic) (CSA) Phencyclidine (Qualitative) (DUID/DRE), 10044U • Urine (Forensic) (CSA) Phencyclidine Confirmation (Drug 55049U Impaired Driving/DRE Toxicology), Urine • (Forensic) (CSA) IN/LA Phencyclidine Confirmation (Qualitative) 54007U • (DUID/DRE), Urine (Forensic)

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 4 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Test Name Test Method / Specimen Stability Scope Units Reference Discontinue Code Name CPT Code Req. Comments

Phencyclidine Confirmation, 52464SP • Serum/Plasma Phencyclidine Confirmation, 5657SP • Serum/Plasma Phencyclidine Confirmation, 50017SP • Serum/Plasma (Forensic) 5657U Phencyclidine Confirmation, Urine • Phencyclidine Confirmation, Urine 50017U • (Forensic) Phencyclidine Confirmation, Urine 52464U • (Forensic) 8761SP Phencyclidine, Serum/Plasma • 8761U Phencyclidine, Urine • Zonisamide Confirmation (DUID/DRE), 54379B • Blood (Forensic) Zonisamide Confirmation (Qualitative) 54379U • (DUID/DRE), Urine (Forensic) Zonisamide Confirmation, Blood 52140B • (Forensic) Zonisamide Confirmation, Serum/Plasma 52140SP • (Forensic) Zonisamide Confirmation, Urine 52140U • (Forensic) 4884SP Zonisamide, Serum/Plasma •

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 5 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes 54212B Bupropion and Metabolite Confirmation (DUID/DRE), Blood (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80338): Bupropion, Hydroxybupropion Method (CPT Code) Compound Name Units Reference Comment Bupropion ng/mL Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.

Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females) Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females) Adults: Single 150 mg SR – 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.

Hydroxybupropion ng/mL 8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.

Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma concentrations: 100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

52012B Bupropion and Metabolite Confirmation, Blood (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80338): Bupropion, Hydroxybupropion Method (CPT Code)

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 6 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes Compound Name Units Reference Comment Bupropion ng/mL Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.

Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females) Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females) Adults: Single 150 mg SR – 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.

Hydroxybupropion ng/mL 8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.

Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma concentrations: 100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

5466B Bupropion and Metabolite Confirmation, Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80338): Bupropion, Hydroxybupropion Method (CPT Code) Compound Name Units Reference Comment Bupropion ng/mL Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.

Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females)

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 7 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes Compound Name Units Reference Comment Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females) Adults: Single 150 mg SR – 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.

Hydroxybupropion ng/mL 8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.

Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma concentrations: 100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

52012SP Bupropion and Metabolite Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80338): Bupropion, Hydroxybupropion Method (CPT Code) Compound Name Units Reference Comment Bupropion ng/mL Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.

Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females) Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females)

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 8 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes Compound Name Units Reference Comment Adults: Single 150 mg SR – 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL

Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.

Hydroxybupropion ng/mL 8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.

Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma concentrations:

100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion

5466SP Bupropion and Metabolite Confirmation, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80338): Bupropion, Hydroxybupropion Method (CPT Code) Compound Name Units Reference Comment Bupropion ng/mL Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.

Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females) Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females) Adults: Single 150 mg SR – 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL

Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 9 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes Compound Name Units Reference Comment Hydroxybupropion ng/mL 8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.

Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma concentrations:

100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion

9122B Bupropion and Metabolite Screen, Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80307): Bupropion, Hydroxybupropion Method (CPT Code) Compound Name Units Reference Comment Bupropion ng/mL Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.

Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females) Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females) Adults: Single 150 mg SR – 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.

Hydroxybupropion ng/mL 8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.

Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 10 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes Compound Name Units Reference Comment concentrations: 100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

9122SP Bupropion and Metabolite Screen, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80307): Bupropion, Hydroxybupropion Method (CPT Code) Compound Name Units Reference Comment Bupropion ng/mL Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.

Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females) Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females) Adults: Single 150 mg SR – 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL

Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.

Hydroxybupropion ng/mL 8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.

Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma concentrations:

100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion

0803B Bupropion and Metabolite, Blood

Summary of Changes: Reference Comment was changed.

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 11 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes Scope of Analysis: LC-MS/MS (80338): Bupropion, Hydroxybupropion Method (CPT Code) Compound Name Units Reference Comment Bupropion ng/mL Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.

Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females) Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females) Adults: Single 150 mg SR – 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.

Hydroxybupropion ng/mL 8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.

Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma concentrations: 100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

0803SP Bupropion and Metabolite, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80338): Bupropion, Hydroxybupropion Method (CPT Code)

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 12 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes Compound Name Units Reference Comment Bupropion ng/mL Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.

Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females) Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females) Adults: Single 150 mg SR – 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL

Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.

Hydroxybupropion ng/mL 8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.

Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma concentrations:

100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion

54215B Carbamazepine and Metabolite Confirmation (DUID/DRE), Blood (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 54215U Carbamazepine and Metabolite Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52015B Carbamazepine and Metabolite Confirmation, Blood (Forensic)

Summary of Changes: Stability was changed.

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 13 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52015SP Carbamazepine and Metabolite Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52015U Carbamazepine and Metabolite Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 0970B Carbamazepine and Metabolite, Blood

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 0970SP Carbamazepine and Metabolite, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 0975SP Carbamazepine-10,11-Epoxide, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 0975U Carbamazepine-10,11-Epoxide, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 14 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes 2915U Dextro / Levo Methorphan - Total, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 54452U Dextro / Levo Methorphan Confirmation - Total (Qualitative) (DUID/DRE), Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52481U Dextro / Levo Methorphan Confirmation - Total, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 9205U Dextro / Levo Methorphan Screen - Total, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 5495U Dextro/Levo Methorphan Confirmation - Total, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52451SP Dextro/Levo Methorphan Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s) 5495SP Dextro/Levo Methorphan Confirmation, Serum/Plasma

Summary of Changes: Stability was changed.

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 15 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes Stability: Room Temperature: 7 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s) 9205SP Dextro/Levo Methorphan Screen, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s) 2915SP Dextro/Levo Methorphan, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s) 2917U Dextromethorphan and Metabolite Ratio - Total, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 10153U Dextrorphan / Levorphanol - Total, Urine (CSA)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 54349U Dextrorphan / Levorphanol Confirmation - Total (Qualitative) (DUID/DRE), Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52061U Dextrorphan / Levorphanol Confirmation - Total, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 16 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes 5497U Dextrorphan / Levorphanol Confirmation - Total, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52061SP Dextrorphan / Levorphanol Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 12 month(s) 5117SP Dextrorphan / Levorphanol Confirmation, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 12 month(s) 9206U Dextrorphan / Levorphanol Screen - Total, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 2506SP Dextrorphan / Levorphanol Screen, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 12 month(s) 54252U Guaifenesin Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52052B Guaifenesin Confirmation, Blood (Forensic)

Summary of Changes: Stability was changed.

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 17 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes Stability: Room Temperature: 1 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 24 month(s) 52052SP Guaifenesin Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52052U Guaifenesin Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 2185B Guaifenesin, Blood

Summary of Changes: Stability was changed.

Stability: Room Temperature: 1 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 24 month(s) 2185SP Guaifenesin, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 2185U Guaifenesin, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 54259B Lamotrigine Confirmation (DUID/DRE), Blood (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 18 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes 54259U Lamotrigine Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52059B Lamotrigine Confirmation, Blood (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52059SP Lamotrigine Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52059U Lamotrigine Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 2484B Lamotrigine, Blood

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 2484SP Lamotrigine, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 2484U Lamotrigine, Urine

Summary of Changes: Stability was changed.

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 19 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 55060U Methadone Confirmation (Drug Impaired Driving/DRE Toxicology), Urine (Forensic) (CSA) IN/LA

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 24 month(s) 10038SP Methadone and Metabolite (DUID/DRE), Serum/Plasma (Forensic) (CSA)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 2 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 12 month(s) 10038U Methadone and Metabolite (Qualitative) (DUID/DRE), Urine (Forensic) (CSA)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 24 month(s) 55047U Methadone and Metabolite Confirmation (Drug Impaired Driving/DRE Toxicology), Urine (Forensic) (CSA) IN/LA

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 24 month(s) 54005U Methadone and Metabolite Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 24 month(s) 50015SP Methadone and Metabolite Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 2 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 12 month(s)

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 20 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes 5682SP Methadone and Metabolite Confirmation, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 2 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 12 month(s) 50015U Methadone and Metabolite Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 24 month(s) 5682U Methadone and Metabolite Confirmation, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 24 month(s) 8722SP Methadone and Metabolite, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 2 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 12 month(s) 8722U Methadone and Metabolite, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 24 month(s) 3225SP Nuedexta®, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s) 54293B Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation (DUID/DRE), Blood (Forensic)

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 21 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52093B Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Blood (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52093SP Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52093U Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 3265B Oxcarbazepine/Eslicarbazepine Acetate as Metabolite, Blood

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 3265SP Oxcarbazepine/Eslicarbazepine Acetate as Metabolite, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 10044SP Phencyclidine (DUID/DRE), Serum/Plasma (Forensic) (CSA)

Summary of Changes: Stability was changed.

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 22 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes Stability: Room Temperature: 7 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s) 10044U Phencyclidine (Qualitative) (DUID/DRE), Urine (Forensic) (CSA)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s) 55049U Phencyclidine Confirmation (Drug Impaired Driving/DRE Toxicology), Urine (Forensic) (CSA) IN/LA

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s) 54007U Phencyclidine Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s) 50017SP Phencyclidine Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s) 52464SP Phencyclidine Confirmation, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s) 5657SP Phencyclidine Confirmation, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 23 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes 50017U Phencyclidine Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s) 52464U Phencyclidine Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s) 5657U Phencyclidine Confirmation, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s) 8761SP Phencyclidine, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s) 8761U Phencyclidine, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s) 54379B Zonisamide Confirmation (DUID/DRE), Blood (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 54379U Zonisamide Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)

Summary of Changes: Stability was changed.

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 24 of 25 Effective Date: Monday, January 08, 2018 Test Updates

Test Changes Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52140B Zonisamide Confirmation, Blood (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52140SP Zonisamide Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 52140U Zonisamide Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s) 4884SP Zonisamide, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 25 of 25